Weighted Average Number of Shares Outstanding, Basic of Blueprint Medicines Corp from 31 Dec 2014 to 31 Mar 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Blueprint Medicines Corp quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 31 Dec 2014 to 31 Mar 2025.
  • Blueprint Medicines Corp Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Mar 2025 was 64,096,000, a 4.1% increase year-over-year.
  • Blueprint Medicines Corp annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 62,857,000, a 3.8% increase from 2023.
  • Blueprint Medicines Corp annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 60,558,000, a 1.5% increase from 2022.
  • Blueprint Medicines Corp annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 59,642,000, a 1.9% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Blueprint Medicines Corp Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 64,096,000 +2,516,000 +4.1% 01 Jan 2025 31 Mar 2025 10-Q 01 May 2025 2025 Q1
Q4 2024 62,857,000 +2,299,000 +3.8% 01 Oct 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
Q3 2024 63,381,000 +2,693,000 +4.4% 01 Jul 2024 30 Sep 2024 10-Q 30 Oct 2024 2024 Q3
Q2 2024 62,854,000 +2,338,000 +3.9% 01 Apr 2024 30 Jun 2024 10-Q 01 Aug 2024 2024 Q2
Q1 2024 61,580,000 +1,454,000 +2.4% 01 Jan 2024 31 Mar 2024 10-Q 01 May 2025 2025 Q1
Q4 2023 60,558,000 +916,000 +1.5% 01 Oct 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
Q3 2023 60,688,000 +930,000 +1.6% 01 Jul 2023 30 Sep 2023 10-Q 30 Oct 2024 2024 Q3
Q2 2023 60,516,000 +899,000 +1.5% 01 Apr 2023 30 Jun 2023 10-Q 01 Aug 2024 2024 Q2
Q1 2023 60,126,000 +814,000 +1.4% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024 2024 Q1
Q4 2022 59,642,000 +1,124,000 +1.9% 01 Oct 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
Q3 2022 59,758,000 +1,111,000 +1.9% 01 Jul 2022 30 Sep 2022 10-Q 26 Oct 2023 2023 Q3
Q2 2022 59,617,000 +1,211,000 +2.1% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 59,312,000 +1,289,000 +2.2% 01 Jan 2022 31 Mar 2022 10-Q 04 May 2023 2023 Q1
Q4 2021 58,518,000 01 Oct 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
Q3 2021 58,647,000 +3,478,000 +6.3% 01 Jul 2021 30 Sep 2021 10-Q 01 Nov 2022 2022 Q3
Q2 2021 58,406,000 +4,189,000 +7.7% 01 Apr 2021 30 Jun 2021 10-Q 02 Aug 2022 2022 Q2
Q1 2021 58,023,000 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q3 2020 55,169,000 +6,248,000 +13% 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021 2021 Q3
Q2 2020 54,217,000 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q3 2019 48,921,000 +5,005,624 +11% 01 Jul 2019 30 Sep 2019 10-Q 29 Oct 2020 2020 Q3
Q1 2019 44,096,806 +396,580 +0.91% 01 Jan 2019 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 43,867,000 +6,074,071 +16% 01 Oct 2018 31 Dec 2018 10-K 17 Feb 2021 2020 FY
Q3 2018 43,915,376 +4,785,275 +12% 01 Jul 2018 30 Sep 2018 10-Q 30 Oct 2018 2018 Q3
Q2 2018 43,856,352 +5,081,761 +13% 01 Apr 2018 30 Jun 2018 10-Q 01 Aug 2018 2018 Q2
Q1 2018 43,700,226 +10,510,467 +32% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q4 2017 37,792,929 +10,301,260 +37% 01 Oct 2017 31 Dec 2017 10-K 26 Feb 2019 2018 FY
Q3 2017 39,130,101 +11,879,439 +44% 01 Jul 2017 30 Sep 2017 10-Q 30 Oct 2018 2018 Q3
Q2 2017 38,774,591 +11,604,168 +43% 01 Apr 2017 30 Jun 2017 10-Q 01 Aug 2018 2018 Q2
Q1 2017 33,189,759 +6,101,840 +23% 01 Jan 2017 31 Mar 2017 10-Q 02 May 2018 2018 Q1
Q4 2016 27,491,669 01 Oct 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
Q3 2016 27,250,662 01 Jul 2016 30 Sep 2016 10-Q 31 Oct 2017 2017 Q3
Q2 2016 27,170,423 01 Apr 2016 30 Jun 2016 10-Q 02 Aug 2017 2017 Q2
Q1 2016 27,087,919 01 Jan 2016 31 Mar 2016 10-Q 03 May 2017 2017 Q1

Blueprint Medicines Corp Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 62,857,000 +2,299,000 +3.8% 01 Jan 2024 31 Dec 2024 10-K 13 Feb 2025 2024 FY
2023 60,558,000 +916,000 +1.5% 01 Jan 2023 31 Dec 2023 10-K 13 Feb 2025 2024 FY
2022 59,642,000 +1,124,000 +1.9% 01 Jan 2022 31 Dec 2022 10-K 13 Feb 2025 2024 FY
2021 58,518,000 +3,984,000 +7.3% 01 Jan 2021 31 Dec 2021 10-K 15 Feb 2024 2023 FY
2020 54,534,000 +6,705,000 +14% 01 Jan 2020 31 Dec 2020 10-K 16 Feb 2023 2022 FY
2019 47,829,000 +3,962,000 +9% 01 Jan 2019 31 Dec 2019 10-K 17 Feb 2022 2021 FY
2018 43,867,000 +6,074,071 +16% 01 Jan 2018 31 Dec 2018 10-K 17 Feb 2021 2020 FY
2017 37,792,929 +10,301,260 +37% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2019 2018 FY
2016 27,491,669 +9,256,055 +51% 01 Jan 2016 31 Dec 2016 10-K 26 Feb 2019 2018 FY
2015 18,235,614 +16,815,096 +1184% 01 Jan 2015 31 Dec 2015 10-K 21 Feb 2018 2017 FY
2014 1,420,518 01 Jan 2014 31 Dec 2014 10-K 09 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.